Previous 10 | Next 10 |
home / stock / alt / alt articles
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
LOS ANGELES, May 10, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on b...
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action laws...
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ:ALT). Share...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and ...
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Altimmune, Inc. (N...
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, not...
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the ...
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Altimmune, Inc. (NASDAQ:ALT)? Did you purc...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Toronto, Canada and Lima, Peru – TheNewswire - July 15, 2024 – Alturas Minerals Corp. (the “Company”) (TSX-V, BVL: ALT) is pleased to provide an update on the Lease agreement with Sociedad Contractual Minera Resguardo (“Minera...
2024-07-11 10:45:04 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $16.74 with volume of 18,885,597 and a one day change of $0.37 (2.23%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-07-10 06:41:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies ha...